Jacobs D B, Hayes G R, Lockwood D H
Department of Medicine, University of Rochester School of Medicine and Dentistry, New York 14642.
Diabetes. 1989 Feb;38(2):205-11. doi: 10.2337/diab.38.2.205.
The in vitro effects of the sulfonylurea glyburide on insulin binding and action were compared in adipocytes from control and nonketotic streptozocin-induced diabetic rats. Adipose tissue from control and diabetic animals was maintained in the absence or presence of 2 micrograms/ml glyburide for 20 h. Insulin binding and insulin-stimulated glucose transport were examined in adipocytes prepared from this tissue. As expected, insulin binding was increased in adipocytes from diabetic animals. Exposure of tissue to glyburide did not influence insulin binding in either control or diabetic cells. Glucose transport activity of diabetic cells, assessed with 2-deoxyglucose, was decreased 30-40% in both the absence (basal) and presence of insulin compared with controls. Glyburide potentiated insulin's effects in both control (15-20%) and diabetic (30-40%) adipocytes. As a result, glucose transport activity in glyburide-treated diabetic cells was restored to a level similar to that of control cells not exposed to the drug. The mechanism by which glyburide potentiated glucose transport activity was examined with the D-glucose-displaceable cytochalasin B-binding technique to measure glucose-transporter concentration in membranes prepared from control and diabetic adipocytes exposed to the drug. Adipocytes from this model of diabetes are known to have a decreased cellular content of glucose transporters. The concentration of glucose transporters was decreased by 31% in plasma membranes from insulin-treated diabetic cells. There were corresponding decreases in diabetic microsomal and total membrane fractions. There was also a 40% decrease in the translocation of transporters from the microsomes to the plasma membrane in response to insulin in diabetic cells.(ABSTRACT TRUNCATED AT 250 WORDS)
比较了磺脲类药物格列本脲对正常大鼠和非酮症链脲佐菌素诱导的糖尿病大鼠脂肪细胞胰岛素结合及作用的体外效应。将正常和糖尿病动物的脂肪组织在不存在或存在2微克/毫升格列本脲的情况下维持20小时。检测由此制备的脂肪细胞中的胰岛素结合及胰岛素刺激的葡萄糖转运。正如预期的那样,糖尿病动物的脂肪细胞中胰岛素结合增加。组织暴露于格列本脲对正常或糖尿病细胞中的胰岛素结合均无影响。与正常对照相比,用2-脱氧葡萄糖评估的糖尿病细胞的葡萄糖转运活性在无胰岛素(基础)和有胰岛素存在时均降低30-40%。格列本脲增强了正常(15-20%)和糖尿病(30-40%)脂肪细胞中胰岛素的作用。结果,经格列本脲处理的糖尿病细胞中的葡萄糖转运活性恢复到与未接触该药物的正常对照细胞相似的水平。采用D-葡萄糖可置换的细胞松弛素B结合技术检测格列本脲增强葡萄糖转运活性的机制,以测量由接触该药物的正常和糖尿病脂肪细胞制备的膜中葡萄糖转运体的浓度。已知该糖尿病模型的脂肪细胞中葡萄糖转运体的细胞含量减少。胰岛素处理的糖尿病细胞的质膜中葡萄糖转运体的浓度降低了31%。糖尿病微粒体和总膜部分也相应减少。糖尿病细胞中,胰岛素刺激下转运体从微粒体向质膜的转位也减少了40%。(摘要截短于250字)